Get startedLog in
    Picture of Biosenic SA logo

    BIOS — Biosenic SA News Story

    0.000.00%
    be flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapValue Trap
    All News

    Brief: Biosenic Announces New Developments In Phase 2 Clinical Trial For Arsenic Trioxide In cGvHD

    Picture of Biosenic SA logoBiosenic SA
    27/09/2023 06:07
    Sept 27 (Reuters) - Bone Therapeutics SA  BIOS.BR :
    * BIOSENIC PERFORMS FURTHER ANALYSIS OF ITS PHASE 2 CLINICAL
TRIAL
DATA, LEADING TO AN OPTIMAL ADMINISTRATION SCHEME FOR ITS NEXT
LATE-STAGE TRIAL OF ARSENIC TRIOXIDE IN CGVHD
    * NEW POST-HOC ANALYSIS SUGGESTS A REPEATED ADMINISTRATION
CYCLE
FOR BIOSENIC'S UPCOMING PHASE 3 TRIAL OF ORAL ARSENIC TRIOXIDE
(ATO) IN CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
    * BIOSENIC EXPECTS THUS TO GET CLOSER TO OPTIMAL CONDITIONS
FOR A
CURATIVE TREATMENT FOR CGVHD, FOR WHICH THERE IS CURRENTLY NO
SATISFACTORY THERAPY

Source text for Eikon:  ID:nGNE4r9d7k 
Further company coverage:  BIOS.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;))

    Recent news on Biosenic SA

    See all news